Will Spironolactone Cause False‑Positive or False‑Negative 24‑Hour Urine Aldosterone Results?
Spironolactone will cause a false‑positive (falsely elevated) 24‑hour urine aldosterone result, not a false‑negative. Mineralocorticoid receptor antagonists must be withdrawn for at least 4 weeks before any confirmatory aldosterone testing, including 24‑hour urine aldosterone measurement 1.
Mechanism of Interference
Spironolactone blocks mineralocorticoid receptors in the kidney, which triggers a compensatory physiologic response: the adrenal glands increase aldosterone production in an attempt to overcome the receptor blockade 2, 3.
This reactive rise in aldosterone secretion occurs because spironolactone normalizes plasma renin and potassium levels—both of which are potent stimulators of aldosterone synthesis—yet the drug simultaneously prevents aldosterone from exerting its effect at the receptor level 2.
In patients with idiopathic hyperaldosteronism (bilateral adrenal hyperplasia), spironolactone treatment causes urinary aldosterone excretion to increase from baseline levels (22.3 ± 2.5 μg/24 h) to nearly triple (69.3 ± 10.3 μg/24 h), demonstrating that the drug provokes aldosterone hypersecretion rather than suppressing it 2.
Even in patients with aldosterone‑producing adenomas—where autonomous secretion is less responsive to physiologic regulation—spironolactone maintains elevated aldosterone levels rather than reducing them, with urinary aldosterone remaining at 51.4 ± 7.3 μg/24 h during treatment 2.
Clinical Implications for Diagnostic Testing
You cannot reliably confirm or exclude primary aldosteronism while a patient is taking spironolactone because the drug artificially elevates both plasma and urinary aldosterone concentrations 1.
The 2024 ESC guidelines explicitly state that mineralocorticoid receptor antagonists interfere with aldosterone‑renin ratio (ARR) interpretation and must be stopped at least 4 weeks before screening or confirmatory testing 4, 1.
If spironolactone cannot be safely discontinued—for example, in patients with severe hypertension or life‑threatening hypokalemia—the diagnosis of primary aldosteronism cannot be definitively confirmed using standard biochemical tests 1.
Recent evidence suggests that ARR testing accuracy is "only marginally impacted" in patients with florid (severe, obvious) primary aldosteronism who remain on spironolactone, but this exception applies only to a narrow subset of patients with extreme biochemical abnormalities 4.
Practical Washout Protocol
Discontinue spironolactone at least 4 weeks before any aldosterone testing—whether screening with ARR or performing confirmatory tests such as oral sodium loading with 24‑hour urine aldosterone or intravenous saline suppression 1, 5.
During the washout period, substitute non‑interfering antihypertensive agents: long‑acting calcium channel blockers (e.g., amlodipine, verapamil slow‑release) and alpha‑receptor antagonists (e.g., prazosin, doxazosin) minimally affect the ARR and can be used to maintain blood pressure control 4, 5.
Correct hypokalemia before testing, targeting serum potassium 4.0–5.0 mEq/L, because low potassium suppresses aldosterone production and causes false‑negative results 1, 5.
Encourage a liberal (unrestricted) salt intake during the washout period, as dietary sodium restriction stimulates renin and lowers the ARR, potentially causing false‑negative screening results 5.
Common Pitfalls to Avoid
Do not attempt to "interpret results in context" of spironolactone use for confirmatory testing—unlike screening ARR (where some guidelines permit testing on medications with contextual interpretation), confirmatory suppression tests require complete withdrawal of mineralocorticoid receptor antagonists 4, 1.
Do not confuse the direction of interference: spironolactone raises aldosterone levels (false‑positive for hyperaldosteronism), whereas ACE inhibitors, ARBs, and diuretics suppress aldosterone or stimulate renin, causing false‑negative results 5.
Do not use alternative potassium‑sparing diuretics (e.g., amiloride, triamterene) as substitutes during the washout period—although they lack anti‑androgenic effects, they still interfere with aldosterone physiology and must also be discontinued before testing 5.